Janice Schwartz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Janice Schwartz has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Alain Hovnanian
INSERM UMR 1163, Laboratory of genetic skin diseases, Imagine Institute of Genetic Diseases, University Paris Cité and Department of Genomic Medicine of Rare Diseases, AP-HP, Hôpital Necker-Enfants Malades, Paris, France
5 shared publications - Edel A. O'TOole
Centre for Cell Biology and Cutaneous Research, Blizard Institute, Queen Mary University of London, London, UK
5 shared publications - Amy S. Paller
Departments of Dermatology and Pediatrics Northwestern University Feinberg School of Medicine Chicago Illinois USA
3 shared publications - Antoni Gostynski
Department of Dermatology, Maastricht UMC+ Centre of Expertise for Genodermatoses, Maastricht University Medical Centre+ , Maastricht
3 shared publications - Mandy Aldwin-Easton
Ichthyosis Support Group, Earley, Reading, Berkshire, UK
3 shared publications - Pierre A. Coulombe
University of Michigan
3 shared publications
Latest Publications
- Open Access
- 24 January 2026
- Published by Elsevier in Journal of Investigative Dermatology
Proteomics reveals altered lipid biosynthesis and keratin hyperphosphorylation in pachyonychia congenita
- 24 January 2026
- Published by Elsevier in Journal of Investigative Dermatology
Open AccessProteomics reveals altered lipid biosynthesis and keratin hyperphosphorylation in pachyonychia congenita
- 2 July 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (9) , 2127-2130
The Importance of Shared Patient Voices in Advancing Science for Genodermatoses on a Global Scale
- 2 July 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (9) , 2127-2130
The Importance of Shared Patient Voices in Advancing Science for Genodermatoses on a Global Scale
- Top Cited PapersOpen Access
- 1 May 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (4) , 619-641
Nonsyndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy
Epidermal differentiation disorders (EDDs) encompass inherited conditions characterized by abnormal epidermal differentiation, including nonsyndromic and syndromic subtypes with more extensive cutaneous involvement or palmoplantar keratoderma. Nonsyndromic EDDs (nEDDs) are defined as disorders that primarily affect large areas of skin and adnexal structures without alterations in extracutaneous tissues resulting from the underlying genetic change. To facilitate the development of targeted therapies and to provide clinicians with clearer therapeutic guidance, we have developed a new nomenclature for EDDs that includes the causative altered gene and the nEDD subgroup designation, sometimes with a clinical or histological descriptor or acronym. Historically, many nEDDs have been named on the basis of phenotypic characteristics or associations that are now considered outdated or inappropriate. For example, the term ‘harlequin ichthyosis’ evokes potentially stigmatizing images. Similarly, the word ‘ichthyosis’ is derived from the Greek ichthys, meaning fish, and the Greek hystrix, meaning porcupine, further emphasizing the need to abandon derogatory terminology. As a result, the clinical relevance of the previous classification, which included eponymous and/or descriptive titles, has diminished. In the new, gene-based classification, old terms considered pejorative, such as ichthyosis, vulgaris, hystrix and harlequin have been eliminated and eponyms have been replaced. Among the 53 genetically distinct nEDDs are conditions formerly known as autosomal recessive congenital ichthyosis, erythrokeratodermia variabilis et progressiva, Hailey–Hailey disease and Darier–White disease. This review outlines the updated nomenclature and classifications of nEDDs, linked to detailed clinical descriptions and representative photographs to guide practitioners.
- 1 May 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (4) , 619-641
Top Cited PapersOpen AccessNonsyndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy
Epidermal differentiation disorders (EDDs) encompass inherited conditions characterized by abnormal epidermal differentiation, including nonsyndromic and syndromic subtypes with more extensive cutaneous involvement or palmoplantar keratoderma. Nonsyndromic EDDs (nEDDs) are defined as disorders that primarily affect large areas of skin and adnexal structures without alterations in extracutaneous tissues resulting from the underlying genetic change. To facilitate the development of targeted therapies and to provide clinicians with clearer therapeutic guidance, we have developed a new nomenclature for EDDs that includes the causative altered gene and the nEDD subgroup designation, sometimes with a clinical or histological descriptor or acronym. Historically, many nEDDs have been named on the basis of phenotypic characteristics or associations that are now considered outdated or inappropriate. For example, the term ‘harlequin ichthyosis’ evokes potentially stigmatizing images. Similarly, the word ‘ichthyosis’ is derived from the Greek ichthys, meaning fish, and the Greek hystrix, meaning porcupine, further emphasizing the need to abandon derogatory terminology. As a result, the clinical relevance of the previous classification, which included eponymous and/or descriptive titles, has diminished. In the new, gene-based classification, old terms considered pejorative, such as ichthyosis, vulgaris, hystrix and harlequin have been eliminated and eponyms have been replaced. Among the 53 genetically distinct nEDDs are conditions formerly known as autosomal recessive congenital ichthyosis, erythrokeratodermia variabilis et progressiva, Hailey–Hailey disease and Darier–White disease. This review outlines the updated nomenclature and classifications of nEDDs, linked to detailed clinical descriptions and representative photographs to guide practitioners.
- Top Cited PapersOpen Access
- 4 April 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (4) , 592-618
Syndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy
Since the 2010 classification of ichthyoses, our understanding of hereditary epidermal differentiation disorders (EDDs) has markedly increased, allowing for consideration of new therapeutic targets based on disease pathogenesis. A new gene- and protein product function-based classification focuses on shared mechanisms of disease pathogenesis, with the possibility that grouped disorders may respond similarly to new therapeutics. These EDDs have been subdivided into syndromic (sEDD), nonsyndromic with features limited to skin and appendages, and predominantly palmoplantar skin involvement (nonsyndromic and syndromic). sEDDs have clinically important extracutaneous features related to the gene alteration. Often, recognition based on skin manifestations facilitates early gene-based diagnosis, discussion of prognosis, genetic counselling and the initiation of therapy. All sEDDs are rare; the most common are STS-sEDD (formerly known as X-linked ichthyosis) and SPINK5-sEDD (formerly known as Netherton syndrome). Given the rarity, frequent association with early demise and variable clinical features of sEDDs, the natural history of the diseases with advancing age and genotype–phenotype relationships are poorly defined. Of the 51 sEDDs, associated neurological (n = 36; 71%) and/or ophthalmological (n = 25; 49%) findings are most common, and 39% (n = 20) have associated hair abnormalities. The widespread use of topical lovastatin for cholesterol synthesis-related sEDDs represents the prototype of pathogenesis-based therapy. This concept of upstream inhibition to prevent metabolite accumulation and supplementation with the pathway end product potentially applies to other sEDDs, such as those affecting ceramide synthesis and transport. Topical or systemically administered inhibition of activated pathways is another potential approach, exemplified by the emerging treatment of SPINK5-sEDD with kallikrein inhibitors. Many sEDDs may be amenable to gene editing or the introduction of functional cDNA. However, even systemic treatments targeting cutaneous diseases may not address extracutaneous manifestations that arise during embryological development.
- 4 April 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (4) , 592-618
Top Cited PapersOpen AccessSyndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy
Since the 2010 classification of ichthyoses, our understanding of hereditary epidermal differentiation disorders (EDDs) has markedly increased, allowing for consideration of new therapeutic targets based on disease pathogenesis. A new gene- and protein product function-based classification focuses on shared mechanisms of disease pathogenesis, with the possibility that grouped disorders may respond similarly to new therapeutics. These EDDs have been subdivided into syndromic (sEDD), nonsyndromic with features limited to skin and appendages, and predominantly palmoplantar skin involvement (nonsyndromic and syndromic). sEDDs have clinically important extracutaneous features related to the gene alteration. Often, recognition based on skin manifestations facilitates early gene-based diagnosis, discussion of prognosis, genetic counselling and the initiation of therapy. All sEDDs are rare; the most common are STS-sEDD (formerly known as X-linked ichthyosis) and SPINK5-sEDD (formerly known as Netherton syndrome). Given the rarity, frequent association with early demise and variable clinical features of sEDDs, the natural history of the diseases with advancing age and genotype–phenotype relationships are poorly defined. Of the 51 sEDDs, associated neurological (n = 36; 71%) and/or ophthalmological (n = 25; 49%) findings are most common, and 39% (n = 20) have associated hair abnormalities. The widespread use of topical lovastatin for cholesterol synthesis-related sEDDs represents the prototype of pathogenesis-based therapy. This concept of upstream inhibition to prevent metabolite accumulation and supplementation with the pathway end product potentially applies to other sEDDs, such as those affecting ceramide synthesis and transport. Topical or systemically administered inhibition of activated pathways is another potential approach, exemplified by the emerging treatment of SPINK5-sEDD with kallikrein inhibitors. Many sEDDs may be amenable to gene editing or the introduction of functional cDNA. However, even systemic treatments targeting cutaneous diseases may not address extracutaneous manifestations that arise during embryological development.
- 29 October 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (4) , 725-727
Celebrating 20 Years of the International Pachyonychia Congenita Consortium
- 29 October 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (4) , 725-727
Celebrating 20 Years of the International Pachyonychia Congenita Consortium
- 15 December 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (4) , 748-754
Pachyonychia Congenita: A Research Agenda Leading to New Therapeutic Approaches
- 15 December 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (4) , 748-754
Pachyonychia Congenita: A Research Agenda Leading to New Therapeutic Approaches
- 22 September 2022
- Published by Morressier GmbH
ESDR292 - Heterozygous pathogenic variants affecting the the highly conserved VWFA domain of integrin-β4 cause isolated nail dystrophy
Pathogenic variants in ITGB4 cause various forms of autosomal recessive epidermolysis bullosa (EB). ITGB4 encodes integrin-β4, which plays a crit | POSTER
- 22 September 2022
- Published by Morressier GmbH
ESDR292 - Heterozygous pathogenic variants affecting the the highly conserved VWFA domain of integrin-β4 cause isolated nail dystrophy
Pathogenic variants in ITGB4 cause various forms of autosomal recessive epidermolysis bullosa (EB). ITGB4 encodes integrin-β4, which plays a crit | POSTER